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Abstract
Background: The sole effective option for patients with advanced HCC is sorafenib and there is an urgent need to 
develop new therapeutic approaches. Immunotherapy is a promising option that deserves major investigation. In this 
open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination 
with a telomerase peptide (GV1001) vaccination in patients with advanced HCC.
Methods: 40 patients with advanced HCC were treated with 300 mg/m2 cyclophosphamide on day -3 followed by 
GM-CSF + GV1001 vaccinations on days 1, 3, 5, 8, 15, 22, 36 followed by 4-weekly injections. Primary endpoint of this 
phase II trial was tumor response; secondary endpoints evaluated were TTP, TTSP, PFS, OS, safety and immune 
responses.
Results: None of the patients had a complete or partial response to treatment, 17 patients (45.9%) demonstrated a 
stable disease six months after initiation of treatment. The median TTP was 57.0 days; the median TTSP was estimated 
to be 358.0 days. Cyclophosphamide, GV1001 and GM-CSF treatment were well tolerated and most adverse events, 
which were of grade 1 or 2, were generally related to the injection procedure and injection site reactions. GV1001 
treatment resulted in a decrease in CD4+CD25+Foxp3+ regulatory T cells; however, no GV1001 specific immune 
responses were detected after vaccination.
Conclusions: Low dose cyclophosphamide treatment followed by GV1001 vaccinations did not show antitumor 
efficacy as per tumor response and time to progression. Further studies are needed to analyze the effect of a combined 
chemo-immunotherapy to treat patients with HCC.
Trial registration: NCT00444782
Background
Hepatocellular carcinoma (HCC) represents the third
leading cause of cancer related death worldwide. Only a
minority of patients is eligible for potential curative treat-
ments such as surgical resection, liver transplantation
and local ablative therapies [1,2]. Therapeutic options for
patients with advanced HCC are limited. So far,
Sorafenib, a multi-targeted tyrosine kinase inhibitor, is
the only drug, which leads to an increase in overall sur-
vival in patients with advanced HCC as demonstrated in
two randomized phase III placebo-controlled trials [3,4].
Sorafenib delays tumor progression but as it does not
achieve tumor resolution and tumor free long term sur-
vival there is major need to develop new options that
would further increase the current therapeutic benefits,
Therefore, new treatment options are urgently needed for
patients with HCC at several phases of their evolution
and recommendations regarding the optimal trial designs
have been published [2].
Immunotherapy represents a potentially attractive
option for HCC patients [5]. Cancer vaccines using pep-
tides derived from tumor-specific antigens represent one
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potential alternative immunotherapeutic procedure. A
number of different tumor antigens identified in HCC
represent potential antigens for a peptide-based vaccina-
tion approach in patients with HCC [5]. Telomerase
activity has been expressed in numerous tumors includ-
ing HCC [6,7] and immunogenic telomerase peptides
have been characterized [6]. Recently, it has also been
reported that telomerase-specific CD4+ and CD8+ T cell
responses are induced upon vaccination with hTERT-
transfected dendritic cells [8] and vaccination with
telomerase derived peptide, GV1001, was shown to
induce T cell responses in patients with non-resectable
pancreatic cancer and non-small cell lung cancer [9,10].
However, the effect of a cancer vaccine might be inhib-
ited by the presence of CD4+CD25+ regulatory T cells
[11], which are known to suppress the function of anti-
gen-specific T cell responses and are increased in
patients with HCC [12]. Previously, we have been able to
demonstrate that low dose cyclophosphamide treatment
can impair the effect of regulatory T cells in patients with
HCC [13]. Based on these studies we have now investi-
gated the effect of a telomerase peptide (GV1001) cancer
vaccine in combination with a low dose cyclophosph-
amide treatment.
Methods
Patient population
The study population consisted of male or female
patients (≥ 18 years of age) with advanced-stage hepato-
cellular carcinoma, which was either confirmed histologi-
cally or diagnosed according to European Association for
the Study of the Liver criteria of known predisposing
chronic liver disease, alpha-fetoprotein (AFP) > 400 ng/
mL, and characteristic imaging. Patients were classified
as having advanced disease if they were not eligible for or
had disease progression after surgical or locoregional
therapies. The eligibility criteria also included an Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus score of 1 or less, Child-Pugh liver function class A, a
life expectancy of 12 weeks or more, adequate hemato-
logic function (platelet count, ≥ 75-109 per liter; hemoglo-
bin, ≥ 9.0 g per deciliter; white blood cell count ≥ 3.0 ×
109 per liter), total bilirubin, ≤ 2 mg per deciliter [51.3
μmol per liter]; alanine aminotransferase and aspartate
aminotransferase, ≤ 5 times the upper limit of the normal
range) and adequate renal function (serum creatinine, ≤
1.5 mg per deciliter [132 μmol per liter]). Patients were
required to have at least one untreated target lesion that
could be measured in one dimension, according to the
Response Evaluation Criteria in Solid Tumors (RECIST).
Patients with known co-existing autoimmune diseases or
HIV infection were excluded from the study. Patients
were not eligible if they had received any type of an anti-
tumor treatment or corticosteroids within the 4 weeks of
pre-treatment with cyclophosphamide. All patients pro-
vided written informed consent before enrollment in the
study. The study was approved by the institutional review
board or ethics committee at each center and complied
with the provisions of the Good Clinical Practice guide-
lines and the Declaration of Helsinki and local laws. The
trial has been registered in clinicaltrials.gov database
(NCT00444782). At the time of trial initiation the bene-
fits of sorafenib had not been established. Thus only
patients ineligible for therapies with higher priority
(resection, transplantation, ablation and chemoemboliza-
tion) were enrolled as well as patients, who had pro-
gressed under those treatment types. Upon
demonstration of the benefits of sorafenib, the patients
ineligible for sorafenib therapy due to medical reasons
wee also included.
Treatment Plan
Patients received intravenous infusion of 300 mg/m2
cyclophosphamide on day -3 followed by intradermal
immunizations with 0.56 mg GV1001 and 75 μg granulo-
cyte macrophage colony-stimulating-factor (GM-CSF)
on days 1, 3, 5, 8, 15, 22, 36 followed by 4-weekly injec-
tions. Adverse events/toxicities were categorized and
graded by the Common Terminology Criteria of Adverse
Events (version 3.0). There was no dose modification.
Criteria for discontinuation included unacceptable toxici-
ties and symptomatic disease progression defined as a 2-
step increase in the patient's performance status (to be
confirmed after 2 weeks). Additionally, treatments were
stopped for serious concurrent illness or significant wors-
ening of concurrent illness.
Delayed type hypersensitivity (DTH) analysis
DTH skin reaction (size of skin reaction) was examined
48 hours after administration. The DTH-test was consid-
ered positive if the area of the skin reaction had an aver-
age diameter of > 5 mm at 48 hours after administration.
DTH tests were performed on days 1, 8, 15, 22, 36, and at
week 10.
In vitro analysis of immune responses
Peripheral blood mononuclear cells (PBMC) were
obtained from patients by Ficoll density gradient centrif-
ugation (Biochrom, Berlin, Germany) at the indicated
time points as previously described [14]. The following
fluorochrome-labled anti-human antibodies were used in
this study to detect regulatory T cells: anti-CD3 (clone
UCHT1; eBioscience), anti-CD4 (clone RPA-T4, BD
Pharmingen), anti-CD25 (clone 4E3; Miltenyi Biotec),
anti-Foxp3 (clone 206D; Biolegend). Stained cells were
washed and analyzed with a FACSCalibur (BD Biosci-
ences, Heidelberg, Germany) flow cytometer. All data
analysis was performed with CellQuest software (BD Bio-Greten et al. BMC Cancer 2010, 10:209
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sciences, Heidelberg, Germany). Isotype-matched anti-
bodies were used as controls. For analysis of antigen-
specific T cell responses 5 × 105 PBMC were plated in 96
well plates and 1 μM peptide was added. IFN-γ was mea-
sured in supernatants after 24 hours by ELISA and prolif-
eration was measured by H-3 thymidine incorporation
after 72 hours. Antigen-specific T cell responses were
analyzed before treatment and 3, 6 and 12 weeks after
first peptide vaccination.
Statistical analysis
The primary endpoint of this study was response rate
according to RECIST after 6 months [2]. All eligible
patients who began treatment were considered assessable
for the primary end point. The primary efficacy endpoint,
the response rate (CR+PR) according to modified
RECIST, was based on the Best Overall Response and was
to be presented using frequency count and percentage.
The number of patients in the considered analysis popu-
lation was used as denominator for calculation of the rate.
The 95% confidence interval around the response rate
was also to be presented. The analysis of the primary end-
point was to be presented for the Intent-to-Treat (ITT)
population. Secondary end points included TTP, time to
symptomatic progression (TTSP), PFS, toxicity profile
and immune responses. TTSP was defined as the time
from the date of the first administration of GV1001 to the
date of symptomatic progression (a 2-step deterioration
in performance status) or death. The change in perfor-
mance status was confirmed after 2 weeks. Subjects who
had no documented symptomatic progression at the end
of the study or who were lost to follow-up prior to having
symptomatic progression were censored at the date of
their last visit or contact. OS was not a pre-defined End-
point. Kaplan-Meier methodology was used to describe
the distribution of TTP, PFS, TTSP and survival. All anal-
yses were performed using SAS version 8.1 or later (http:/
/www.sas.com; SAS Institute, Cary, NC).
Results
Characteristics of patients
40 patients with advanced HCC (BCLC-C) were enrolled
between November 2006 and April 2008 at three differ-
ent European centers. 14 patients were enrolled in Spain,
12 patients in Germany and 14 patients in France. Alco-
holic liver cirrhosis was the predominant cause of liver
disease (40%) and 95% of the patients had a Child-Pugh A
liver cirrhosis. 26 patients (65%) had a BCLC tumor stage
of C. A summary of the baseline characteristics of all
patients is presented in Table 1. All patients were eligible
for safety and efficacy analysis, with the exception of
three patients, which were not assessable due to clinical
progression or death before the treatment was initiated.
Clinical trial conduct
According to the protocol, the recruitment of patients
was stopped after the first interim analysis once 40
patients had been enrolled in this trial. At this time point
treatment was stopped in 8 patients prior to three
months of treatment, in 16 patients between months 3
and 6, in 7 patients between months 6 and 9 and in 7
patients between months 9 and 12. Two patients received
treatment for more than 12 months. Imaging studies (CT
or MRI) were performed before start of treatment and
every 8 weeks thereafter. However, no objective tumor
responses were detected in any of the patients after 6
months of treatment. All patients were evaluable for
safety analysis and efficacy evaluation.
Table 1: Demographic and baseline characteristics:
Demographics
Age Mean 66.5 ± 10.5
Sex (male/female) 35/5
White/Caucasian 36 (90%)
Cause of disease
HBV/HCV/Ethanol 5 (12.5%)/15 (37.5%)/16 (40%)
ECOG - no (%)
0 31 (77.5%)
1 9 (22.5%)
BCLC stage - no (%)
A2  ( 5 % )
B 12 (30%)
C 26 (65%)
Child - Pugh Score - no (%)
A 38 (95%)
B2  ( 5 % )
Prior Therapies - no (%)
Prior therapy received 26 (65%)
Surgery 9 (23%)
Other type of 
therapy
25 (63%)
Biochemistry profile - 
Median ± SD (range)
ALT (IU/L) 57.8 ± 31.1 (range 16 - 166)
AST (IU/L) 81.2 ± 49.8 (range 23 - 229)
Bilirubin (μmol/L) 17. 7 ± 12.8 (range 5.5 - 54.5)Greten et al. BMC Cancer 2010, 10:209
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Safety events
Patients received a median of 11.0 doses of GV1001
(range 6.0 to 19.0 doses). Sixteen patients (40.0%)
received treatment for a minimum of 6 months. The
overall incidence of treatment-related adverse events was
82.5%. Adverse events related to GV1001, GM-CSF or
cyclophosphamide treatment occurred in 52.5%, 52.5%
and 7.5% respectively. Most reported adverse events were
related to the injection procedure and injection site reac-
tions. The majority of adverse events related to GV1001
o r  G M - C S F  w e r e  p r e d o m i n a n t l y  G r a d e  1 ,  w i t h  a  f e w
Grade 2 events. A similar toxicity profile was observed
for GM-CSF and only 4 adverse events were related to the
pre-treatment with cyclophosphamide. Except for one
case of renal failure (Grade 3), they were all grade 1 or 2
(Table 2).
Efficacy
N o  c o m p l e t e  o r  p a r t i a l  r e s p o n s e s  w e r e  o b s e r v e d  i n
patients treated with low dose cyclophosphamide and
GV1001. Stable disease was observed in 17 patients
(45.9%) as the best response during follow-up. Twenty
patients demonstrated a progressive disease and three
patients were not assessed for tumor response after
screening due to clinical progression or death before
treatment was initiated. The majority of patients (35
patients, 87.5%) had tumor progression by the end of the
study. 5 patients were lost to follow-up. The median TTP
for the patients was 57.0 days (95% CI 52.0 - 102) as
shown in Figure 1. The evaluation of TTSP showed that a
total of 21 patients (52.5%) in the ITT population had
symptomatic progression (a 2-step deterioration in per-
formance status) or died prior to the end of the study, and
19 patients (47.5%) were censored at the date of their last
visit or contact as they had no documented symptomatic
progression at the end of the study. The median TTSP
was estimated to be 358.0 days (95% CI: 217.0; -) (Figure
1). A total of 36 patients (90%) in the ITT population had
tumor progression or death from any cause prior to the
end of the study. The median PFS was 57.0 days (95% CI
52.0 - 96.0) (Figure 2). Finally, overall survival was ana-
lyzed in the patient population. The estimated median
OS for the ITT population was 358.0 days (95% CI 217;
upper limit could not be calculated) (Figure 2).
Immune response analysis
Three patients responded to the DTH test. However, two
of these patients already demonstrated a DTH response
prior to immunization. One patient demonstrated a DTH
response 2 weeks after vaccination. However, this DTH
response was not observed at any of the later time points.
T-cell responses have only been carried out for patients
treated at one of the three sites (Germany) for logistic
reasons. The frequency of CD4+CD25+Foxp3+ regulatory
T cells was determined by FACS analysis before and five
days after cyclophosphamide treatment. A decrease in
the relative frequency of CD4+CD25+Foxp3+ regulatory T
cells was found in 6/11 patients (54.5%) (Figure 3).
GV1001 specific T cell responses were analyzed by
cytokine secretion as well as proliferation analysis. How-
ever no clear GV1001 specific T cell responses were
observed in any of the patients after pretreatment with
cyclophosphamide and immunization with GM-CSF and
GV1001 peptide (Figure 4).
Discussion and conclusion
Until recently, no systemic treatment has shown any ben-
efits for patients with advanced HCC. The breakthrough
Table 2: Incidence of drug-related adverse events
Adverse event Grade 1/2 (*) 3 (†)
Overall incidence 33 (any grade)
Injection site conditions 9/0 0
Pyrexia 2/1 0
Erythema 5/0 0
Renal failure 0/0 1
* Only side effects, which have occured in more than 5% of the patients are listed
† Any grade 3 adverse event has been listed
Figure 1 Kaplan-Meier Analysis of Time to Progression (TTP) and 
Time to Symptomatic Progression (TTSP). The median TTP was 57 
days (1.9 months) and the TTSP was 358 days (11.7 months).Greten et al. BMC Cancer 2010, 10:209
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results obtained with sorafenib have represented a major
step in the management of this deadly disease that now
has an option of similar efficacy as that of agents used for
other cancers such as lung and colorectal [15]. Unfortu-
nately the impact of sorafenib is not the final answer.
Tumor growth is significantly delayed and survival is
improved, but ultimately the HCC progresses and
patients die because of cancer. This shows the need to
develop new agents that would further expand the bene-
fits of current therapy [16]. Major interest is being placed
in the evaluation of other molecular therapies to be given
in association to sorafenib or upon sorafenib failure, thus
opening the field for second line options. In addition to
agents modulating the activation of signaling cascades,
there is a known potential in priming immune response
against cancer cells to overcome the immune escape that
malignant cells are able to establish as a prominent fea-
ture [5]. Several approaches to induce immune reactiva-
tion to control cancer have been tested [17]. In this
investigation, we have evaluated the effect of a telomerase
derived peptide vaccine in combination with low dose
cyclophosphamide treatment in a single arm phase II
trial. The primary efficacy variable for this study was
overall response; however, there were no complete or
partial responses during this study. The best overall
tumor response (according to RECIST) for the ITT popu-
lation was stable disease for 17 patients (45.9%). In a
recent placebo-controlled phase III study on Sorafenib in
advanced HCC patients (SHARP trial), none of the
patients had a complete response, but 2% of the patients
in the Sorafenib group had a partial response and 71%
had stable disease (according to RECIST) maintained for
at least 28 days after the first demonstration [3]. However,
in the Sorafenib study, tumor measurements were per-
formed every 6 weeks whereas in the present study CT
scans were performed every 8 weeks, which makes direct
comparison of tumor response between studies difficult.
Nonetheless, the TTP detected in our study with a less
frequent timing is shorter than that registered both in the
SHARP and in the Asian Pacific trials. Hence, vaccine
therapy using GV1001 has not evidenced any efficacy in
terms of tumor response and TTP. This has been recently
suggested to be the optimal end-point to register the
potential efficacy of agents where no major reduction in
tumor mass is to be expected [2]. The validity of the con-
cept has been shown in the sorafenib studies and cur-
rently, most investigations are designed to capture at the
Figure 2 Kaplan-Meier Analysis of Overall Survival and Progres-
sion Free Survival. Among 40 patients, the median overall survival 
was 358 days (11.7 months) and the progression free survival was 57 
days (1.9 months).
Figure 3 Analysis of CD4+CD25+Foxp3+ regulatory T cells in HCC 
patients prior to cyclophosphamide treatment and after 5 days.
Figure 4 Analysis of GV1001 specific T cell responses by ELISA (A) 
and thymidine incorporation (B) in HCC patients before and after 
peptide vaccination. Among 11 patients analyzed no definite anti-
gen-specific T cell responses were noticed.Greten et al. BMC Cancer 2010, 10:209
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same time TTP and tumor response according to conven-
tional RECIST with the modifications reflected in the
JNCI AASLD guidelines [2].
In the present study, the majority of patients (35
patients; 87.5%) in the ITT population had disease pro-
gression by the end of the study with a median TTP of
57.0 days (95% CI: 52.0; 102.0). Median PFS was also 57.0
days (95% CI: 52.0; 96.0). In the Sorafenib study, the
median time to radiologic progression was 5.5 months in
the Sorafenib group and 2.8 months in the placebo group
[3]. It should be noted, however, that the baseline charac-
teristics of the patients in the Sorafenib study were differ-
ent to the baseline characteristics of the patients in the
present study. Only patients with an ECOG performance
status 0 or 1 were enrolled in the present study, whereas
7-8% of patients in the Sorafenib study had an ECOG per-
formance status 2 at baseline. Furthermore, more patients
in the present study (77.5%) had an ECOG performance
s t a t u s  0  a t  b a s e l i n e  c o m p a r e d  w i t h  p a t i e n t s  i n  t h e
Sorafenib study (54%). Similarly, more patients in the
present study had a BCLC stage of A or B (35%) at base-
line compared with patients in the Sorafenib study (18%).
Hence, patients in the present study tended to have less
advanced disease at baseline compared with the baseline
status of patients in the Sorafenib study. Despite this, the
median TTP was shorter in patients in the present study
than in patients in the placebo group of the Sorafenib
study. However, median OS was 358.0 days (95% CI:
217.0; upper limit not calculable) (11.5 months) in com-
parison to 10.7 months in the Sorafenib group and 7.9
months in the placebo group of the SHARP trial [3]. The
longer median OS in patients treated with GV1001 com-
pared with the median OS in both the placebo and
patients in the SHARP trial could be explained by the bet-
ter baseline condition of the patients in the present study.
This is why overall survival should not be an informative
endpoint in phase 1-2 studies as the bias in the selection
of patients for an experimental intervention sure can
induce a survival that might be misleadingly. It could be
argued that vaccination could take some time to be effec-
tive and hence delay late tumor progression, while at early
follow-up time points, the benefit would not be captured.
Such an evaluation would require a different study design
and development of assessment criteria that are not avail-
able and validated. In addition, after detecting tumor pro-
gression within this investigation, patients may have
engaged in other experimental approaches and thus, it is
unfeasible to explore this later evolutionary profile.
In contrast to previous studies in which patients with
pancreatic cancer or non-small lung cancer were immu-
nized with GV1001 [9,10], no clear GV1001 specific
immune responses were observed in HCC patients after
treatment with low dose cyclophosphamide followed by
repetitive GM-CSF/GV1001 immunizations. We cannot
exclude that the pre-treatment administration of a single
dose of 300 mg/m2 cyclophosphamide in this trial with
the purpose of overcoming the effects of inhibitory
e f f e c t s  b y  r e g u l a t o r y  T  c e l l s  m a y  h a v e  i n f l u e n c e d  t h e
immune responses in the DTH test as well as our ex vivo
T cell analysis. However, based on the results from our
previous trial, in which we treated advanced HCC
patients only with cyclophosphamide [13], we did not
expect any effects on antigen-specific T cell responses
since in this trial cyclophosphamide treatment had no
significant effect on the frequency of CD4+ or CD8+ T
c e l l s .  I n  c o n t r a s t ,  w e  w e r e  a b l e  t o  d e t e c t  s p o n t a n e o u s
tumor-specific immune responses after cyclophosph-
amide treatment in a limited number of patients. More-
over, low dose cyclophosphamide treatment has also
been used in a number of other clinical trials, where it
potentially supported the effect of different vaccines
[18,19] and no effect on antigen-specific immune
responses were observed in a number of different preclin-
ical studies in mice [20-22].
Cyclophosphamide, GV1001 and GM-CSF treatment
were in general well tolerated in this study. There were no
adverse events > CTC 2 for GV1001 or GM-CSF treat-
ment and the majority of the observed adverse events
were related to the injection procedure and injection site
reactions. One Grade 3 adverse event (renal failure) was
observed in a patient treated with cyclophosphamide,
which was reversible. Therefore the treatment was much
less toxic than other treatments such as sorafenib [3] or
other molecular targeting agents [16].
In summary, our study failed to demonstrate significant
tumor responses. This might be due to the fact, that in
contrast to other GV1001 immunization trials, no clear
immune responses (DTH or T cell responses) have been
observed in this study. One possibility is the addition of
cyclophosphamide in order to target regulatory T cells or
the nature of the disease, although clear T cell responses
have been observed in other vaccination trials [23-25].
Further studies are needed to analyze the effect of a com-
bined chemo-immunotherapy, which will be interesting
in light of recent data, which suggest that Sorafenib,
which has become the standard of care for patients with
advanced HCC has significant effects on tumor-specific
immune responses [26,27].
Competing interests
This study was supported by Pharmexa A/S Biosciences to TFG, MB and JB.
Authors' contributions
TFG, MB and JB were critically involved in the study design, statistical analysis.
TFG, AF, GK, NB, CA, MPM, MB and JB recruited patients for this trial. TFG, FK and
LAO were involved in the analysis of regulatory T cells. TFG drafted the manu-
script, which was revised by FK, MB and JB. All authors have read and approved
the final manuscript.
Acknowledgements
We thank the patients who participated in the study and their families.Greten et al. BMC Cancer 2010, 10:209
http://www.biomedcentral.com/1471-2407/10/209
Page 7 of 7
Author Details
1Department of Gastroenterology, Hepatology and Endocrinology, Hannover 
Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany, 2Twincore 
Center for Experimental and Clinical Infection Research, Feodor-Lynen Strasse 
7-9, 30625 Hannover, Germany, 3Service d'Hepato-Gastroenterologie, Hopital 
Jean Verdier AP-HP, Universite' Paris XIII, Bondy 93143, Cedex, France, 4BCLC 
Group, Liver Unit, Hospital Clínic. University of Barcelona. IDIBAPS. CIBEREHD. 
Villarroel 170, Barcelona 08036, Spain, 5Department of Legal Medicine, 
University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, 
Germany and 6Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 
10 Rm 12N226, 9000 Rockville Pike, Bethesda MD 20892, USA
References
1. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, 
Klempnauer J, Galanski M, Manns MP: Survival rate in patients with 
hepatocellular carcinoma: a retrospective analysis of 389 patients.  Br J 
Cancer 2005, 92(10):1862-1868.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman 
M, Schwartz M, Lotze M, Talwalkar J, et al.: Design and endpoints of 
clinical trials in hepatocellular carcinoma.  Journal of the National Cancer 
Institute 2008, 100(10):698-711.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, 
Santoro A, Raoul JL, Forner A, et al.: Sorafenib in advanced hepatocellular 
carcinoma.  The New England Journal of Medicine 2008, 359(4):378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang 
TS, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific 
region with advanced hepatocellular carcinoma: a phase III 
randomised, double-blind, placebo-controlled trial.  Lancet Oncol 2009, 
10(1):25-34.
5. Greten TF, Manns MP, Korangy F: Immunotherapy of hepatocellular 
carcinoma.  Journal of Hepatology 2006, 45(6):868-878.
6. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase 
catalytic subunit is a widely expressed tumor-associated antigen 
recognized by cytotoxic T lymphocytes.  Immunity 1999, 10(6):673-679.
7. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, 
Kuzushima K, Takiguchi M, Kaneko S: Cytotoxic T cell responses to 
human telomerase reverse transcriptase in patients with 
hepatocellular carcinoma.  Hepatology 2006, 43(6):1284-1294.
8. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, 
Niedzwiecki D, Boczkowski D, Gilboa E, et al.: Telomerase mRNA-
transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T 
cell responses in patients with metastatic prostate cancer.  J Immunol 
2005, 174(6):3798-3807.
9. Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, Buanes 
T, Gaudernack G: Telomerase peptide vaccination of patients with non-
resectable pancreatic cancer: A dose escalating phase I/II study.  Br J 
Cancer 2006, 95(11):1474-1482.
10. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, 
Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA, et al.: Telomerase 
peptide vaccination: a phase I/II study in patients with non-small cell 
lung cancer.  Cancer Immunol Immunother 2006, 55(12):1553-1564.
11. Terabe M, Berzofsky JA: Immunoregulatory T cells in tumor immunity.  
Curr Opin Immunol 2004, 16(2):157-162.
12. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy 
F: Increased populations of regulatory T cells in peripheral blood of 
patients with hepatocellular carcinoma.  Cancer Res 2005, 
65(6):2457-2464.
13. Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M, 
Manns MP, Korangy F: Low-dose cyclophosphamide treatment impairs 
regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in 
patients with advanced HCC.  J Immunother 2010, 33(2):211-218.
14. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, 
Greten TF, Korangy F: A new population of myeloid-derived suppressor 
cells in hepatocellular carcinoma patients induces 
CD4(+)CD25(+)Foxp3(+) T cells.  Gastroenterology 2008, 135(1):234-243.
15. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular 
carcinoma.  Hepatology 2008, 48(4):1312-1327.
16. Greten TF, Korangy F, Manns MP, Malek NP: Molecular therapy for the 
treatment of hepatocellular carcinoma.  Br J Cancer 2009, 100(1):19-23.
17. Greten TF, Manns MP, Korangy F: Immunotherapy of HCC.  Rev Recent 
Clin Trials 2008, 3(1):31-39.
18. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, 
Nemunaitis J, Le D, Sugar E, et al.: Allogeneic granulocyte macrophage 
colony-stimulating factor-secreting tumor immunotherapy alone or in 
sequence with cyclophosphamide for metastatic pancreatic cancer: a 
pilot study of safety, feasibility, and immune activation.  Clin Cancer Res 
2008, 14(5):1455-1463.
19. Rozkova D, Tiserova H, Fucikova J, Last'ovicka J, Podrazil M, Ulcova H, 
Budinsky V, Prausova J, Linke Z, Minarik I, et al.: FOCUS on FOCIS: 
combined chemo-immunotherapy for the treatment of hormone-
refractory metastatic prostate cancer.  Clin Immunol 2009, 131(1):1-10.
20. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, 
Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells 
suppress tumor immunity but are sensitive to cyclophosphamide 
which allows immunotherapy of established tumors to be curative.  Eur 
J Immunol 2004, 34(2):336-344.
21. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, 
Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM: Recruitment of 
latent pools of high-avidity CD8(+) T cells to the antitumor immune 
response.  The Journal of Experimental Medicine 2005, 201(10):1591-1602.
22. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: 
Inhibition of CD4(+)25+ T regulatory cell function implicated in 
enhanced immune response by low-dose cyclophosphamide.  Blood 
2005, 105(7):2862-2868.
23. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, 
Todd K, Glaspy JA, McBride WH, et al.: T-cell responses to HLA-A*0201 
immunodominant peptides derived from alpha-fetoprotein in patients 
with hepatocellular cancer.  Clin Cancer Res 2003, 9(16 Pt 1):5902-5908.
24. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran 
SD, Hernandez J, Seja E, Potter DM, et al.: A phase I/II trial testing 
immunization of hepatocellular carcinoma patients with dendritic cells 
pulsed with four alpha-fetoprotein peptides.  Clin Cancer Res 2006, 
12(9):2817-2825.
25. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, 
Kerr DJ, Young LS, Adams DH: A phase II study of adoptive 
immunotherapy using dendritic cells pulsed with tumor lysate in 
patients with hepatocellular carcinoma.  Hepatology 2009, 
49(1):124-132.
26. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, 
Singh-Jasuja H, Brossart P: Sorafenib, but not sunitinib, affects function 
of dendritic cells and induction of primary immune responses.  Blood 
2008, 111(12):5610-5620.
27. Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D: MAPK-
independent impairment of T-cell responses by the multikinase 
inhibitor sorafenib.  Mol Cancer Ther 2009, 8(2):433-440.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/209/prepub
doi: 10.1186/1471-2407-10-209
Cite this article as: Greten et al., A phase II open label trial evaluating safety 
and efficacy of a telomerase peptide vaccination in patients with advanced 
hepatocellular carcinoma BMC Cancer 2010, 10:209
Received: 10 November 2009 Accepted: 17 May 2010 
Published: 17 May 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/209 © 2010 Greten et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:209